These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 25841802)

  • 1. Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab.
    Berti A; Cavalli G; Campochiaro C; Guglielmi B; Baldissera E; Cappio S; Sabbadini MG; Doglioni C; Dagna L
    Semin Arthritis Rheum; 2015 Aug; 45(1):48-54. PubMed ID: 25841802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
    Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: A retrospective analysis of 455 patients from a single center in China.
    Chang DY; Li ZY; Chen M; Zhao MH
    Semin Arthritis Rheum; 2019 Feb; 48(4):701-706. PubMed ID: 29887327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of interleukin-32 and interleukin-6 in granulomatosis with polyangiitis and microscopic polyangiitis: association with clinical and biochemical findings.
    Krajewska Wojciechowska J; Kościelska-Kasprzak K; Krajewski W; Morawski K
    Eur Cytokine Netw; 2019 Dec; 30(4):151-159. PubMed ID: 32096477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review.
    Sakai R; Kondo T; Kurasawa T; Nishi E; Okuyama A; Chino K; Shibata A; Okada Y; Takei H; Nagasawa H; Amano K
    Clin Rheumatol; 2017 Oct; 36(10):2383-2392. PubMed ID: 28733791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective Role of HLA-DRB1*13:02 against Microscopic Polyangiitis and MPO-ANCA-Positive Vasculitides in a Japanese Population: A Case-Control Study.
    Kawasaki A; Hasebe N; Hidaka M; Hirano F; Sada KE; Kobayashi S; Yamada H; Furukawa H; Yamagata K; Sumida T; Miyasaka N; Tohma S; Ozaki S; Matsuo S; Hashimoto H; Makino H; Arimura Y; Harigai M; Tsuchiya N
    PLoS One; 2016; 11(5):e0154393. PubMed ID: 27166610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA-associated vasculitis.
    Holding S; Fisher VJ; Abuzakouk M
    Ann Clin Biochem; 2015 Mar; 52(Pt 2):297-301. PubMed ID: 24723621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Anti-Pentraxin-3 Autoantibodies in ANCA-Associated Vasculitis.
    Simon A; Subra JF; Guilpain P; Jeannin P; Pignon P; Blanchard S; Garo E; Jaillon S; Chevailler A; Renier G; Puéchal X; Bottazzi B; Mantovani A; Delneste Y; Augusto JF
    PLoS One; 2016; 11(1):e0147091. PubMed ID: 26797217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) proposed by Japan Otological Society.
    Harabuchi Y; Kishibe K; Tateyama K; Morita Y; Yoshida N; Okada M; Kunimoto Y; Watanabe T; Inagaki A; Yoshida T; Imaizumi M; Nakamura T; Matsunobu T; Kobayashi S; Iino Y; Murakami S; Takahashi H; Tono T
    Auris Nasus Larynx; 2021 Feb; 48(1):2-14. PubMed ID: 32768313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention.
    Kallenberg CG; Stegeman CA; Abdulahad WH; Heeringa P
    Am J Kidney Dis; 2013 Dec; 62(6):1176-87. PubMed ID: 23810690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
    Ozaki S
    Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological drugs in ANCA-associated vasculitis.
    Lutalo PM; D'Cruz DP
    Int Immunopharmacol; 2015 Aug; 27(2):209-12. PubMed ID: 25907243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of neutrophil extracellular trap remnants in the circulation of patients with small vessel vasculitis, but an inverse correlation to anti-neutrophil cytoplasmic antibodies during remission.
    Söderberg D; Kurz T; Motamedi A; Hellmark T; Eriksson P; Segelmark M
    Rheumatology (Oxford); 2015 Nov; 54(11):2085-94. PubMed ID: 26170375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum decoy receptor 3 levels are associated with the disease activity of MPO-ANCA-associated renal vasculitis.
    Maruyama H; Hirayama K; Nagai M; Ebihara I; Shimohata H; Kobayashi M
    Clin Rheumatol; 2016 Oct; 35(10):2469-76. PubMed ID: 27251675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: advances in pathogenesis and treatment].
    Silva F; Cisternas M
    Rev Med Chil; 2013 Jun; 141(6):765-73. PubMed ID: 24121580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A preliminary study of the significance of autoantibodies against light chain of myeloperoxidase on pulmonary damages in myeloperoxidase-antineutrophil cytoplasmic antibody associated vasculitis].
    Zhang L; Shuai Z; Hu Z; Zhang M; Chen S
    Zhonghua Nei Ke Za Zhi; 2015 Jun; 54(6):511-6. PubMed ID: 26359012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
    Harper L; Cockwell P; Adu D; Savage CO
    Kidney Int; 2001 May; 59(5):1729-38. PubMed ID: 11318943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four cases of MPO-ANCA-positive vasculitis with otitis media, and review of the literature.
    Ono N; Yoshihiro K; Oryoji D; Matsuda M; Ueki Y; Uezono S; Kai Y; Himeji D; Niiro H; Ueda A
    Mod Rheumatol; 2013 May; 23(3):554-63. PubMed ID: 22706878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.